News & Events

OGT expands Next Generation Sequencing portfolio

OGT expands Next Generation Sequencing portfolio

New NGS products for streamlined sample prep and ovarian cancer research

Oxford and Cambridge, UK – 4 August 2015 – Oxford Gene Technology (OGT), the molecular genetics company, today announces the expansion of its portfolio of high-quality products for Next Generation Sequencing (NGS) with the addition of the SureSeq™ Ovarian Cancer Panel & SureSeq NGS Library Preparation Kit.

The new products are a result of significant recent investment of OGT’s R&D and commercial capabilities in the area, and will add to OGT’s existing range of NGS products, including the SureSeq Solid Tumour Panel, and the SureSeq Myeloid Panel, which was launched in June. OGT has worked closely with industry-leading experts to ensure the products have the most relevant and up-to-date content combined with simple and streamlined workflows.

Mike Evans, CEO of OGT commented, “NGS is a significant area of growth within the genomics industry and our strategic focus has been directed at driving forward new product development and sales. We have launched three new NGS products this year, and we are generating a strong pipeline of additional products in development.”

The SureSeq Ovarian Cancer Panel is a hybridisation-based enrichment panel which covers all coding exons of seven key genes of importance in ovarian cancer research; BRCA1, BRCA2, TP53, PTEN, ATM, ATR, and NF1. Although now well recognised as providing superior results over amplicon-based enrichment technology, hybridisation-based enrichment has traditionally required more DNA, and the library preparation protocol has been longer and more complex. These issues are overcome with the SureSeq NGS Library Preparation Kit, which streamlines the NGS sample prep workflow to reduce hands-on steps and turnaround times.

The panel allows the detection of germline mutations in DNA derived from blood as well as both germline and somatic mutations in DNA derived from formalin-fixed, paraffin-embedded (FFPE) tissue. Screening for germline mutations in such genes allows research into familial risk of developing breast and ovarian cancer. Analysis of somatic mutations in a tumour can help research into drug response and the development of new therapies. SureSeq Interpret Software, OGT’s freely provided powerful, standalone data analysis package, converts results into an intuitive interactive report which allows for easy filtering of variants without the need for in-house bioinformatics resource. The high sensitivity of the panel enables more accurate detection of low-frequency variants, commonly found in heterogeneous cancer samples, than obtained using alternative NGS techniques.

Find out more about the OGT’s expanding portfolio of SureSeq NGS products at

About Oxford Gene Technology

Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.

For more information on the Company, please visit our website at

CytoSure™, SureSeq™ and Genefficiency™: For Research Use Only; Not for Use in Diagnostic Procedures. Cytocell: Some products may not be available in the US.

Issued for and on behalf of Oxford Gene Technology by Instinctif Partners.
For more information please contact:

back to news